A Phase 2 interventional study of Intravenous iron in POTS - Postural Orthostatic Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center — 2 open to participants now, 13 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · Vanderbilt University Medical Center.
Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, this one is the 12th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 2, reaches primary completion later than 5 of the 12 other live ones, and was the 18th registered.
136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.
Browse Postural Orthostatic Tachycardia Syndrome studies →2 of the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 36 across 102 interventional studies indexed under Postural Orthostatic Tachycardia Syndrome.
Median enrollment 40 across the 13 interventional studies, 70 across the 5 observational. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
5 of the studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT02725060Vanderbilt University Medical CenterAutoimmune Basis for Postural Tachycardia Syndrome | 2027-02 |
| NCT05375968Vanderbilt University Medical CenterSplanchnic Venous Capacitance in Postural Tachycardia Syndrome | 2027-05-31 |
| NCT03124355Vanderbilt University Medical CenterVagal Stimulation in POTS | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot study is to investigate whether giving iron to people with POTS who have low ferritin levels will increase the red blood cell volume and improve POTS symptoms.
This pilot study involves undergoing a physical exam and medical history, answering some questionnaires, and visiting the Vanderbilt Autonomic Dysfunction Center before and 2 months after the iron treatment for bloodwork, blood volume measurements, autonomic function tests, and wearing an activity monitor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Intravenous iron infusion will be administered according to standard clinical care.
Drug: Intravenous iron
The Intravenous iron infusion will be administered according to standard clinical care. The provider will choose the dosage and formulation of IV iron.
Orthostatic tachycardia
Orthostatic tachycardia, defined as the difference between upright and supine heart rates, will be assessed during a 10-minute head-up tilt test.
Time frame: Orthostatic tachycardia will be assessed before iron infusion (Visit 1) and after 2 months of treatment (Visit 2)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2026 → Dec 2026 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron
Postural Orthostatic Tachycardia Syndrome →
Vanderbilt University Medical Center →